Conditions
MASH
3 articles published between June 12, 2026 and November 13, 2026.
WHAT THE STUDY ACTUALLY SAYSIn 381 adults with biopsy-confirmed MASH and stage 2–3 fibrosis, efinopegdutide resolved the disease in most participants at one year. It is a mid-stage trial of a drug that is not approved.
4 min read
THE DRUG DOCKETIn ESSENCE, the first 800 patients with biopsy-confirmed fatty-liver disease were analysed at week 72. Steatohepatitis resolved in 62.9% on semaglutide versus 34.3% on placebo — an interim look at an ongoing trial.
3 min read
THE DRUG DOCKETSYNCHRONIZE-MASLD reports 84.2% of survodutide patients hitting a 30% cut in liver fat at 48 weeks. The trial measured fat on MRI, not fibrosis on biopsy — which is where the harder question still sits.
3 min read
This page indexes this newspaper’s reporting on MASH. It is not a medical reference entry, and nothing here is medical advice. See our editorial standards.